Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel

Gut

Volumn 64, Issue 5, 2015, Pages 700-706

  Duits, Lucas C ^a   Phoa, K Nadine ^a   Curvers, Wouter L ^a   Ten Kate, Fiebo J W ^a,b   Meijer, Gerrit A ^c   Seldenrijk, Cees A ^d   Offerhaus, G Johan ^a,b   Visser, Mike ^a   Meijer, Sybren L ^a   Krishnadath, Kausilia K ^a   Tijssen, Jan G P ^a   Mallant Hent, Rosalie C ^a,e   Bergman, Jacques J G H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e Department of Pathology St Antonius Hospital ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER PROGNOSIS; COHORT ANALYSIS; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HIGH GRADE DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; LOW GRADE DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PATHOLOGIST; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; TUMOR REGRESSION; ADENOCARCINOMA; AGED; DISEASE COURSE; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; RISK ASSESSMENT;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84929452735     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307278     Document Type: Article

References (41)

1. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
2. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009;373:850-61.
3. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.
4. Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus 2007;20:36-41.
5. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
6. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336-46.
7. Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012;143:927-35.
8. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009;69:4112-15.
9. Alvi MA, Liu X, O'Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013;19:878-88.
10. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011;141:1179-86, 1186.e1.
11. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523-30.
12. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
13. Lim C, Treanor D, Dixon M, et al. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy 2007;39:581-7.
14. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32:379-88.
15. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000;96:3071-83.
16. De Jonge PJF, van Blankenstein M, Looman CWN, et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-6.
17. Sikkema M, Looman CWN, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol 2011;106:1231-8.
18. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
19. Hvid-Jensen F, Pedersen L, Drewes A, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
20. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
21. Coco DP, Goldblum JR, Hornick JL, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol 2011;35:45-54.
22. Kerkhof M, van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007;50:920-7.
23. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
24. Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol 2010;8:783-8.
25. Pech O, Vieth M, Schmitz D, et al. Conclusions from the histological diagnosis of low-grade intraepithelial neoplasia in Barrett's oesophagus. Scand J Gastroenterol 2007;42:682-8.
26. Kaye P V, Haider SA, Ilyas M, et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009;54:699-712.
27. Hulscher JB, Haringsma J, Benraadt J, et al. Comprehensive Cancer Centre Amsterdam Barrett Advisory Committee: first results. Neth J Med 2001;58:3-8.
28. Pouw RE, van Vilsteren FGI, Peters FP, et al. Randomized trial on endoscopic resection-cap versus multiband mucosectomy for piecemeal endoscopic resection of early Barrett's neoplasia. Gastrointest Endosc 2011;74:35-43.
29. Herrero LA, van Vilsteren FGI, Pouw RE, et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. Gastrointest Endosc 2011;73:682-90.
30. Van Vilsteren FGI, Phoa KN, Herrero LA, et al. Circumferential Balloon-Based Radiofrequency Ablation of Barrett's Esophagus with Dysplasia Can be Simplified, yet Efficacy Maintained, by Omitting the Cleaning Phase. Clin Gastroenterol Hepatol 2013;11:491-8.
31. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
32. Phoa KN, van Vilsteren FGI, Weusten BLAM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014;311:1209-17.
33. Casparie M, Tiebosch ATMG, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29:19-24.
34. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
35. Cohen J. Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213-20.
36. Altman DG. Practical statistics for medical research. Chapman and Hall, 1991.
37. Singh S, Manickam P, Amin A V, et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:897-909.e4.
38. Vieth M, Schubert B, Lang-Schwarz K, et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 2006;38:1201-5.
39. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 2005;100:775-83.
40. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011;106:1447-55; quiz 1456.
41. Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012;143:567-75.